Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Immunogenicity of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Patients With Lymphoma or Solid Tumor

NCT06521931 is registered in ClinicalTrials.gov with Chongqing Peg-Bio Biopharm Co., Ltd. as lead sponsor.

NCT NCT06521931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06521931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Immunogenicity of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Patients With Lymphoma or Solid Tumor
Lead sponsor
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 6, 2023
Completion date
January 13, 2025
Enrollment
24 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

thrombocytopenia